Lupus Clinical Trials

336 recruitingLast updated: June 18, 2026

There are 336 actively recruiting lupus clinical trials across 69 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3, Phase 4. Top locations include New York, New York, United States, Beijing, Beijing Municipality, China, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Lupus Trials at a Glance

336 actively recruiting trials for lupus are listed on ClinicalTrialsFinder across 6 cities in 69 countries. The largest study group is Phase 1 with 109 trials, with the heaviest enrollment activity in New York, Beijing, and Houston. Lead sponsors running lupus studies include AstraZeneca, The Children's Hospital of Zhejiang University School of Medicine, and Sohag University.

Treatments under study

About Lupus Clinical Trials

Looking for clinical trials for Lupus? There are currently 17 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lupus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lupus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 336 trials

Recruiting
Not Applicable

LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Heinrich-Heine University, Duesseldorf606 enrolled14 locationsNCT05714930
Recruiting
Phase 1

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

Atopic DermatitisLupusHyper IgE Syndrome From STAT3 Mutation+2 more
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled1 locationNCT07262983
Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 1

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

Lupus Nephritis (LN)
Regeneron Pharmaceuticals90 enrolled17 locationsNCT06975787
Recruiting
Phase 1

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Rheumatoid ArthritisSystemic Lupus Erythematosus
AbbVie30 enrolled6 locationsNCT07607964
Recruiting
Phase 3

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

Lupus Erythematosus, SystemicNephritis, Lupus
Viatris Innovation GmbH300 enrolled11 locationsNCT07201129
Recruiting

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

Systemic Lupus Erythematosus (SLE)Primary Ovarian Insufficiency (Poi)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)100 enrolled1 locationNCT05567198
Recruiting

Patient-Centered Assessment of Symptoms and Outcomes

Myalgic Encephalomyelitis/Chronic Fatigue SyndromeCancerFatigue+5 more
National Center for Complementary and Integrative Health (NCCIH)692 enrolled1 locationNCT03952624
Recruiting
Phase 1

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

SLE (Systemic Lupus)Diffuse Cutaneous Systemic SclerosisSystemic Sclerosis+4 more
CRISPR Therapeutics80 enrolled14 locationsNCT06925542
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
UCB Biopharma SRL450 enrolled230 locationsNCT06617325
Recruiting
Phase 1Phase 2

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

CAR-T CellSLESystemic Lupus Erythematosus (SLE)+4 more
Children's Hospital of Philadelphia24 enrolled1 locationNCT06839976
Recruiting
Phase 4

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

Lupus Nephritis
Aurinia Pharmaceuticals Inc.150 enrolled15 locationsNCT07611214
Recruiting
Phase 4

Trial of Belimumab in Early Lupus

Lupus ErythematosusLupus Erythematosus, Systemic
Northwell Health30 enrolled1 locationNCT03543839
Recruiting
Phase 1

NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis

Refractory Lupus NephritisRefractory Systemic Lupus Erythematosus
Guangdong Provincial People's Hospital18 enrolled1 locationNCT06676631
Recruiting

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

lichen planusAtopic DermatitisHidradenitis Suppurativa+9 more
Assistance Publique - Hôpitaux de Paris830 enrolled1 locationNCT06599411
Recruiting

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb223 enrolled64 locationsNCT07175285
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Lupus Erythematosus, Systemic
AstraZeneca150 enrolled18 locationsNCT06897930
Recruiting
Phase 1

US Zamto-cel Autoimmune Diseases

Systemic Lupus ErythematosusDiffuse Cutaneous Systemic SclerosisSystemic Sclerosis (SSc)+1 more
Miltenyi Biomedicine GmbH48 enrolled1 locationNCT06708845
Recruiting
Phase 2

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus
Boehringer Ingelheim405 enrolled139 locationsNCT07409181
Recruiting
Phase 1

A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)

Rheumatoid ArthritisSystemic Lupus Erythematosus
Merck Sharp & Dohme LLC21 enrolled15 locationsNCT07363590